EN DE
Watch Anika Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Anika Therapeutics Inc (ANIK) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Anika Therapeutics Inc stock $9.37, price $14.55, that is 35.6% below the price, quality 58 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AT Anika Therapeutics Inc logo Some data Nov 7, 2026

Anika Therapeutics Inc

ANIK · US
Solid, but very expensive

Our calculation puts a fair price 36% below what the stock costs today.

Low debt
Generates free cash flow
Revenue last quarter +16% vs. a year ago.
Quality 58/100
Mixed vs. peers (6/13)
Insiders bought $41,070 (6M)
Some data
Fair value $9.37 · Strongly overvalued
Weak Growth (revenue 5y −2.9 %/yr in USD)
Loss-making · -3.1% net margin (TTM)
Narrow moat 21/100
Watch Anika Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$45.03 $8.10 Fair Value $9.37 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $8.10 – $45.03 · fair‑value band $7.79 – $11.57 · the $14.55 price screens above the $9.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Anika Therapeutics in your weekly email

Every Wednesday you see whether Anika Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.

Show moreShow less

The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.

It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products.

The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Stock analysis

Anika Therapeutics Inc (ANIK) currently trades at $14.55, while our model-based Fair Value estimate is $9.37, 36% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $9.69 per share, and 0 of the 7 models we run sit above the $14.55 price.

Bear case: the Asset-Based group reads lowest at $4.23, and 7 of the 7 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $7.79 (bear) to $11.57 (bull), the price of $14.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Anika Therapeutics Inc reported revenue of $113M in FY2025 versus $148M in FY2021, a compound −6.5%/yr. Reported net income was −$10.9M in FY2025.

Key figures

Market cap $195M Micro · P/S ratio 1.61 · EPS (TTM) $−0.2300 · Net margin −3.1% · Return on equity −2.2% · Return on assets (EBIT) −2.6% (5-year average) · Operating margin 11.4% · Revenue (TTM) $121M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (medium confidence).

What moves the price

The share trades about 34% below its 52-week high and 59% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −36%, ANIK screens richer than that median.

Fair Value models

Bear $7.79 Fair Value $9.37 Bull $11.57
Price $14.55 · Downside -35.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $8.34 $10.27 $12.90 82
Growth DCF $8.34 $9.99 $12.07 80
5Y Revenue Exit $7.61 $9.35 $11.57 74
All 7 models by family
DCF Models
FCF DCF $8.34 $10.27 $12.90 82
5Y Revenue Exit $7.61 $9.35 $11.57 74
10Y Revenue Exit $7.79 $9.37 $11.48 68
Multiples
EV/Revenue $5.30 $6.57 $7.84 54
Asset-Based
NCAV (Graham) $2.79 $4.23 $5.28 55
Growth DCF
Growth DCF $8.34 $9.99 $12.07 80
Rev-Margin DCF $7.61 $9.38 $11.48 74

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 50
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 64
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $41,070, on Aug 4, 2026.

  • BuyGary P FischettiDirector2,000 shares at $20.54$41,070Aug 4, 2026
  • BuyJohn B Henneman IIIDirector5,000 shares at $14.66$73,300May 1, 2026
  • BuyStephen D. GriffinPresident and CEO, Director12,200 shares at $12.29$149,938Apr 30, 2026

Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Start year 2020 (pandemic). Over 10 years: +2.0% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21.7% (2020) → −9.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +19.3% a year for the price.

ANIK screens overvalued: fair value 36% below the price. Compare with Merck KGaA →

Compare Anika Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −35.6% · Below median
Profitability
Return on assets −5.7% · Bottom 25%
Net margin (12 months) −3.1% · Bottom 25%
Operating margin (12 months) 11.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 15.6% · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.36× · Cheaper than median
P/S (12 months) 1.62× · Cheaper than median
Price / free cash flow (fiscal year) 44.8× · Priciest 25%
EV/EBITDA 45.4× · Priciest 25%
PEG 2.03× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)78 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs ANIK
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs ANIK
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs ANIK
Haleon plc HLN $9.14 $8.61 −6% vs ANIK
Merck KGaA MRK €148.75 €109.18 −27% vs ANIK
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs ANIK
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs ANIK
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs ANIK
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs ANIK
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs ANIK

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Anika Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Anika Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/ANIK

Frequently asked questions

Is Anika Therapeutics Inc (ANIK) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $9.37 versus a price of $14.55, about 36% lower (overvalued).
What is the fair value of ANIK?
Our model-based fair value for Anika Therapeutics Inc is $9.37 (as of Nov 7, 2026), built from audited fundamentals. The current price: $14.55.
What is the quality score of ANIK?
Anika Therapeutics Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anika Therapeutics Inc (ANIK)?
Our model-based price target is the fair value of $9.37 (as of Nov 7, 2026) from 7 valuation models. Cautious scenario $7.79, optimistic scenario $11.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Anika Therapeutics Inc stock forecast for 2026?
Our models put fair value at $9.37, about 36% lower versus a price of $14.55 (overvalued). Cautious scenario $7.79, optimistic scenario $11.57. The calculation is refreshed regularly with new filings.
What is the revenue of Anika Therapeutics Inc (ANIK)?
Anika Therapeutics Inc reported trailing-twelve-month revenue of about $121M (latest available figure, as of Nov 7, 2026).
What growth is priced into Anika Therapeutics Inc (ANIK)?
For today's price to be fair in a discounted-cash-flow model, Anika Therapeutics Inc would have to grow free cash flow by +22.2 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of ANIK use?
Our models discount Anika Therapeutics Inc at 11.2 %: a base by market capitalisation (micro), damped by beta 0.21, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Anika Therapeutics Inc that is +22.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Anika Therapeutics Inc (ANIK) delivered so far?
Over the past 5 years revenue at Anika Therapeutics Inc grew -2.9 % a year. The price currently implies free-cash-flow growth of +22.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Anika Therapeutics Inc (ANIK) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Anika Therapeutics Inc (+22.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Anika Therapeutics Inc (ANIK)?
The free-cash-flow yield on the price is 2.23 %: that much free cash flow Anika Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Anika Therapeutics Inc (ANIK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anika Therapeutics Inc it is $9.37 per share (as of Nov 7, 2026), against a price of $14.55. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Anika Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ANIK trades above its calculated fair value: price $14.55, fair value $9.37, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANIK?
No. The price is what the market pays today ($14.55); the fair value is what the company's own numbers justify ($9.37). For Anika Therapeutics Inc the two are $5.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anika Therapeutics Inc worth?
The market values Anika Therapeutics Inc at about $195M (market capitalisation, as of Nov 7, 2026). Per share that is $14.55; our models calculate a fair value of $9.37 per share.
What do the bullish and bearish scenarios say about ANIK?
Our models span a range for Anika Therapeutics Inc: cautious scenario $7.79, base $9.37, optimistic $11.57 per share (as of Nov 7, 2026, price $14.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ANIK?
The PEG ratio of Anika Therapeutics Inc is 2.03 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Anika Therapeutics Inc (ANIK)?
Balance-sheet figures for Anika Therapeutics Inc (as of Nov 7, 2026): return on equity −2.2%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is ANIK from its 52-week high?
Anika Therapeutics Inc trades at $14.55, about 34% below its 52-week high of $22.03 and 59% above the low of $9.13 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $9.37 is for.
Which stocks are comparable to Anika Therapeutics Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anika Therapeutics Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $14.55, calculated fair value $9.37 (−36%), Quality Score 58/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANIK calculated?
We run Anika Therapeutics Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $9.37 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Anika Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anika Therapeutics Inc (ANIK)?
The closing price on Nov 6, 2026 was $14.55. Our model-based fair value is $9.37, about 36% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anika Therapeutics Inc right now?
The price sits above even our optimistic bull case ($11.57). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Anika Therapeutics Inc

How large is the market capitalisation of Anika Therapeutics Inc (ANIK)?
The market capitalisation of Anika Therapeutics Inc is $195M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anika Therapeutics Inc (ANIK)?
The price-to-sales ratio of Anika Therapeutics Inc is 1.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Anika Therapeutics Inc (ANIK)?
Earnings per share at Anika Therapeutics Inc are $−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Anika Therapeutics Inc (ANIK)?
The net margin of Anika Therapeutics Inc is −3.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anika Therapeutics Inc (ANIK)?
The return on equity (ROE) of Anika Therapeutics Inc is −2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anika Therapeutics Inc (ANIK)?
On an EBIT basis the return on assets of Anika Therapeutics Inc is −2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anika Therapeutics Inc (ANIK)?
The operating margin of Anika Therapeutics Inc is 11.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anika Therapeutics Inc (ANIK)?
Revenue at Anika Therapeutics Inc is growing +15.6% versus a year earlier (3y avg −10.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Anika Therapeutics Inc (ANIK)?
Earnings per share at Anika Therapeutics Inc are growing −50.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Anika Therapeutics Inc (ANIK) hold?
Anika Therapeutics Inc holds more cash than debt, $31.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Anika Therapeutics Inc in the live analysis

One click puts Anika Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.